Loading clinical trials...
Loading clinical trials...
This clinical trial is intended to investigate a possible effect of the CYP 2C9 inhibitor fluconazole on the bioavailability of olodaterol
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Boehringer Ingelheim
NCT06631261 · Bronchiectasis Adult, Healthy Controls Group - Age and Sex-matched
NCT07258836 · Neoplasms, Healthy
NCT07545590 · Healthy
NCT00090662 · Healthy Volunteer
NCT07059858 · Intellectual Disability, Healthy Subjects
1222.48.1 Boehringer Ingelheim Investigational Site
Berlin
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions